ClinicalTrials.gg
RecruitingNCT06318923COSMOSUpdated Mar 20, 2024

Social and Moral Cognition in Multiple Sclerosis

An interventional study of Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment and MS questionnaire in Multiple Sclerosis, sponsored by Lille Catholic University. Recruiting at 2 sites in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Lille Catholic University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Multiple Sclerosis by Lille Catholic University — 5 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Lille Catholic University.

Planned enrollment
4th of 11
90 · median 46
Started
2023
the only one that year
No phase
11 of 18
4 open now
Registered
16th of 18
by date

Among the 18 studies in Multiple Sclerosis by Lille Catholic University, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 11 with no phase, and was the 16th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 18 studies in Multiple Sclerosis by Lille Catholic University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Multiple Sclerosis by Lille Catholic University, or all of them as a file.
02

Study summary

Multiple Sclerosis (MS) is a chronic, progressive disease that affects young adults (aged between 20 and 40) and has a major impact on patients' quality of life. Cognitive disorders in MS are common, affecting 40-60% of patients. Among these disorders, the presence of social cognition disorders is common. Within social cognition, the moral judgment has been an object of research in order to understand the determinants of moral decision-making: how and why individuals make moral choices with regard to a set of prescriptions and social norms. Compared to control subjects, MS patients show a decrease in moral permissiveness, as well as an increase in moral relativity and emotional reactivity. Thus, it would seem that MS patients issue more deontological choices (lower moral permissiveness). Given that these patients also exhibit empathy deficits and higher alexithymia, these patterns are surprising. Indeed, in other clinical populations, low empathic abilities and high alexithymia are linked to utilitarian rather than deontological moral judgments.

The objective of this project is to analyze the process of decision-making carried out by patients during moral dilemma situations in comparison with control individuals and verify whether the presence of a positivity bias could explain the more deontological choices made by some patients. Indeed, some work has shown that older individuals make more deontological moral judgments than younger adults. These results are also observed with young individuals when their future temporal perspectives have been experimentally constrained.

Read the detailed description

Among the explanatory factors of interest, motivational factors (future temporal perspectives and emergence of a positivity bias), as well as cognitive and affective factors (by means of neuropsychological assessment) and neurophysiological factors (by means of electrodermal response) will be investigated.

From a clinical point of view, a change in decision-making concerning choices with a strong emotional valence can have an impact on patients' daily lives and their course of care. Indeed, MS patients regularly have to make crucial choices about their treatment and care. A modification of decision-making patterns in these situations would represent a major challenge. A good understanding of these patterns will thus contribute to the development of appropriate management procedures to mitigate the impact on patients' daily lives.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 to 55.
  • Understanding and able to express themselves in French.
  • Characteristics according to groups:
  • MS patient group:

    • relapsing-remitting form (RRMS)
    • with EDSS ≤ 4
    • with no significant motor, cerebellar or somesthesic disorders of the upper limbs or visual disorders (specific EDSS parameter ≤ 2)
    • absence of relapse in the last 6 weeks
  • Control groups:

    • absence of known global cognitive deterioration.
  • Understanding and signing of the and information letter concerning participation in the study.
  • Beneficiary of health insurance coverage.

Exclusion criteria

Exclusion Criteria:

  • People with previous neurological pathologies, head trauma with loss of consciousness, known psychiatric pathologies (excluding anxiety-depressive syndrome), serious general illnesses, perceptual or dysarthric disorders preventing verbal communication or reading,
  • Severe cognitive impairment in MS patients, i.e. an SDMT score \< -2.5 if the BICAMS battery is present in the patient's file and is less than 6 months old.
  • Severe depressive syndrome, with a BDI-FS score > 10
  • People with sensory disorders (visual and auditory) that interfere with neuropsychological testing;
  • Major sensory disorders or cerebellar syndrome
  • Sensory deficits (visual or auditory)
  • Treatment with psychotropic drugs
  • Adults under guardianship, curatorship, persons deprived of liberty.
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Other
    Multiple sclerosis patients

    MS patients with the relapsing-remitting form (RRMS) and Expanded Disability Status Scale (EDSS) ≤ 4

    Other: Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment · Other: MS questionnaire

  • Other
    Control participants

    Patients without global cognitive impairment

    Other: Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment · Other: MONTREAL COGNITIVE ASSESSMENT (MoCA) test

Interventions

  • OtherSocio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment

    The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders. The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study. Affective disorders will be assessed using the following tests: * The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression, * State trait anxiety inventory-Y (STAI-Y) to assess anxiety, * Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia, * The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy, * The Dot Probe Task to assess participants' emotional information processing style.

  • OtherMS questionnaire

    This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.

  • OtherMONTREAL COGNITIVE ASSESSMENT (MoCA) test

    The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).

06

What researchers measure

Primary outcomes

  1. Moral dilemma judgments

    The measure will be carried out using a series of 20 vignettes.These vignettes present different scenarios of fictional moral dilemmas, and the subject must make a choice. This test therefore results in 20 binary measures, which can be separated according to the type of scenario. In this task, for each vignette, the type of choice made is measured, along with levels of moral permissibility, subjective emotional reactivity and moral relativity. For this scale: Type of choice: binary yes/no (utilitarian/deontological) ; reflects an answer type (no better or worse outcome) Moral permissibility: Likert Scale from 0 to 10 ; reflects an answer type (no better or worse outcome) Subjective emotional reactivity : Likert Scale from 0 to 10 ; reflects an answer type (no better or worse outcome) Subjective emotional r

    Time frame: 3 hours

Secondary outcomes

  1. Explicit time perspective inventory test

    Participants indicate, on scales ranging from 1 (not at all) to 5 (completely) their levels of agreement on 10 items assessing their future time perspective (e.g. "I plan to set many new goals for myself in the future"). A total score is extracted.

    Time frame: 3 hours

  2. Implicit time perspective inventory test

    Participants are presented with 20 fill-in-the-blank words. These words can be completed either with words referring to future time ("target words"), or with neutral words. The percentage of target words is extracted.

    Time frame: 3 hours

  3. Dot Probe Task

    This task allows us to assess whether individuals tend to pay more attention to positive or negative information. During the dot-probe task, participants are situated in front of a computer screen and asked to stare at a fixation cross on the center of the screen. Two stimuli, one of which is neutral and one of which is threatening, appear randomly on either side of the screen. The stimuli are presented for a predetermined length of time (most commonly 500ms), before a dot is presented in the location of one former stimulus. Participants are instructed to indicate the location of this dot as quickly as possible, either via keyboard or response box. Latency is measured automatically by the computer. The fixation cross appears again for several seconds and then the cycle is repeated. Quicker reaction time to the dot when it occurs in the previous location of a threatening stimulus is interpreted as vigilance to threat.

    Time frame: 3 hours

  4. Level of moral permissibility

    This test aims to measure to what extent the participant finds the proposed solution acceptable. For example: How acceptable do you find it to activate the switch in this situation? An 11-point Likert scale is displayed, ranging from "Not at all" to "Absolutely".

    Time frame: 3 hours

  5. Level of emotional reactivity

    This test aims to measure the individual's emotional (subjective) reaction to a moral dilemma. For example: What emotion does this situation arouse in you? An 11-point Likert scale is displayed, ranging from "None" to "Intense emotion".

    Time frame: 3 hours

  6. Moral relativity level

    This test aims to measure to what extent the participant feels this choice is consensual. For example: Out of 100 people who responded to this scenario, how many would answer as you do? An 11-point Likert scale is displayed below the question, ranging from 0% to 100%.

    Time frame: 3 hours

  7. Brief International Cognitive Assessment for Multiple Sclerosis

    This test enables the assessment of cognitive disorders. The battery's 3 component tests are as follows: * California Verbal Learning Test (CVLT): This test is based on a master list of 16 words belonging to 4 distinct semantic categories . The list is presented 5 times, with the patient asked to recall it immediately after each presentation and after a 20-minute delay. A main score is extracted. * Brief Visuo-spatial Memory Test (BVMT): This test involves 6 simple geometric drawings. 3 presentation/recall phases follow one another, during which the patient is shown the sheet for 10 seconds, followed by an immediate recall phase. A delayed recall phase (at 7 minutes) is also proposed. A main score is extracted. * Symbol Digit Modalities Test (SDMT): a coding test in which the patient has 90 seconds to orally state the correspondence of digits (from 1 to 9) to 9 different symbols (matched according to a correspondence standard). The number of correct answers is measured.

    Time frame: 3 hours

  8. The Beck Depression Inventory

    This is a 21-question multiple-choice self-report inventory, for measuring the severity of depression. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores are as follows: 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. Higher total scores indicate more severe depressive symptoms.

    Time frame: 3 hours

  9. State-Trait Anxiety Inventory

    The State-Trait Anxiety Inventory is one of the first tests to assess both state and trait anxiety separately. Each type of anxiety has its own scale of 20 different questions that are scored.\[10\] Scores range from 20 to 80, with higher scores correlating with greater anxiety.

    Time frame: 3 hours

  10. Toronto Alexithymia Scale (TAS)-20

    The TAS-20 is a self-report scale that is comprised of 20 items. Items are rated using a 5-point Likert scale whereby 1 = strongly disagree and 5 = strongly agree. There are 5 items that are negatively keyed (items 4, 5, 10, 18 and 19). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.

    Time frame: 3 hours

  11. Empathy quotient-8 (EQ-8)

    This is an 8-item self-questionnaire. Subjects are asked to self-assess their level of empathy by positioning themselves, for each item, on a rating scale from 1 to 5 (1 = completely disagree and 5 = completely agree). The total score is analyzed.

    Time frame: 3 hours

  12. Electrodermal response

    During performance of the moral judgment task, an electrodermal response recording device will be installed via two electrodes placed on the participant's non-dominant hand to measure objective emotional reactivity. Individuals' signals are examined in relation to their own baseline levels (without stimuli, Baseline measure), which will serve as a reference for interpreting the signals obtained during the task.

    Time frame: 3 hours

07

Study locations

2 of 2 sites recruiting
  • Hôpital Saint-Vincent-de-Paul - Neurologie
    Lille, France
    Recruiting
    • Béatrice DEGRAEVE · Contact
    • Laurent ZIKOS · Sub investigator
  • Hôpital Saint-Philibert - Neurologie
    Lomme, France
    Recruiting
    • Béatrice DEGRAEVE · Contact
    • Laurent ZIKOS · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2025, 16 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartActual
Dec 19, 2023
Primary completionEst.
Apr 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318923
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Dec 19, 2023
Primary completion
Apr 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Mar 20, 2024

Study contacts

Marie Paule LEBITASY
Contact
Lebitasy.Marie-Paule@ghicl.net
03.20.22.57.41
Audrey TOIA
Contact
toia.audrey@ghicl.net
03.20.22.57.33
Béatrice DEGRAEVE
principal investigator · Catholic University of Lille Faculty of Letters and Humanities

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion